ClinicalTrials.gg
RecruitingNCT07370688IRON TAVIUpdated Jan 27, 2026

Iron Infusion in Patients Undergoing Transcatheter Aortic Valve Implantation

A Phase 4 interventional study of Intravenous ferric carboxymaltose in Aortic Valve Stenosis, Iron Deficiency and TAVI(Transcatheter Aortic Valve Implantation), sponsored by Erasmus Medical Center. Recruiting at 1 site in Netherlands. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-01-27.

Sponsored by Erasmus Medical Center · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 5 months after the study started (first participant enrolled Aug 2024, registered Jan 2026).
  • Started Aug 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
402
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Aortic Valve Stenosis by Erasmus Medical Center — 3 open to participants now, 3 under way, none of them phase 3. Aortic Valve Stenosis · Erasmus Medical Center.

Started
2024
the only one that year
Phase 4
Only one
of the 10
Registered
9th of 10
by date

Among the 10 studies in Aortic Valve Stenosis by Erasmus Medical Center, this one is the only one that started in 2024, is the only one in phase 4, and was the 9th registered.

Aortic Valve Stenosis

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

3 of the 10 studies in Aortic Valve Stenosis by Erasmus Medical Center are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Aortic Valve Stenosis by Erasmus Medical Center, or all of them as a file.
02

Study summary

The aim of the open-label, randomized controlled superiority IRON TAVI trial is to investigate whether intravenous iron therapy (ferric carboxymaltose) improves Health-Related Quality of Life (HRQOL) in patients with severe aortic stenosis (AS) and iron deficiency (ID), undergoing transcatheter aortic valve implantation (TAVI).

The main questions it aims to answer are:

  1. Does intravenous iron therapy improve HRQOL after TAVI in patients with severe AS and ID compared to no intravenous iron therapy (standard of care)?
  2. Can intravenous iron therapy enhance exercise capacity, as measured by the 6-minute walk test, after TAVI in patients with severe AS and ID compared to no intravenous iron therapy (standard of care)?

The intervention group (receiving iron therapy after TAVI) will be compared to the control group (receiving no iron therapy after TAVI (standard of care)).

Participants will:

  • Provide written informed consent
  • Be randomly assigned to one of two groups:

    1. Intervention group: receiving intravenous iron therapy after TAVI (1-3 administrations in the course of 12 weeks)
    2. Control group: receiving standard of care (= no iron therapy)
  • Complete assessments of HRQOL and the 6-minute walk test at baseline and week 24 after TAVI.
  • During follow-up visits, other clinical parameters will be collected (i.e. laboratory status, mortality status, adverse clinical events)
03

Conditions studied

  • Aortic Valve Stenosis
  • Iron Deficiency
  • TAVI(Transcatheter Aortic Valve Implantation)
  • Cardiovascular Diseases

Keywords

  • Health-related Quality of Life
  • Six-Minute Walk Test
  • Randomized Controlled Trial
  • Aortic Valve Stenosis
  • Intravenous Iron Therapy
  • Kansas City Cardiomyopathy Questionnaire
  • Functional Recovery
  • Iron Deficiency
  • Cardiovascular Diseases
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient age ≥ 65 years
  • Patients with severe AS and ID undergoing successful TAVI
  • ID defined as Ferritin \< 100 ug/L and/or Transferrin saturation \< 20%
  • Ability to perform assessment of QoL (questionnaire assessment) and EC (6-MWT)
  • Signed

Exclusion criteria

Exclusion Criteria:

  • for TAVI
  • Ferritin > 400 ug/L
  • \<5.6 mmol/L or \<9 g/dL
  • Hemoglobin >8.7 mmol/L or >14 g/dL in men and >8.1 mmol/L or >13 g/dL in women
  • Anaemia due to known reasons other than ID and/or anticipated non-response to iron-supplementation (e.g. hemogobinopathy, bone marow disease, active cancer, unresolved active bleeding)
  • Chronic liver disease (including active hepatitis) and/or screening or aspartate transaminase above three times the .
  • Renal dialysis (previous, current, or planned within the next 6 months) or /CKD-EPI estimated glomerular filtration rate \<15 mL/min.
  • History of iron overload
  • History of erythropoietin, i.v. or oral iron therapy, and blood transfusion in previous 3 months and/or such therapy planned within next 6 months
  • Clinically apparent infection requiring antibiotic treatment
  • Known to iFCM or to any of its
  • Pregnancy
  • Study subject participation in another TAVI related clinical study in which the primary endpoint includes mortality, hospitalization for heart failure and/or quality of life assessment.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
402 participants (estimated)

Study arms

  • Experimental
    Intervention arm

    Receiving intravenous iron therapy (ferric carboxymaltose) after TAVI, administered in 1-3 settings over the course of 12 weeks.

    Drug: Intravenous ferric carboxymaltose

  • No intervention
    Control arm

    Receiving standard of care, i.e. no intravenous iron therapy (ferric carboxymaltose) after TAVI.

Interventions

  • DrugFerric carboxymaltoseStudies of Ferric carboxymaltoseFerric carboxymaltose pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The intervention involves the administration of intravenous ferric carboxymaltose (FCM) to correct iron deficiency (ID) in patients with severe aortic stenosis. FCM will be delivered in 1 to 3 settings, depending on the patient's baseline hemoglobin level, body weight, and persistence of ID after the initial administration(s): 1. Setting-1: After successful TAVI and before hospital discharge, a maximum of 1000 milligrams of FCM will be administered. 2. Setting-2: A second dose of 500-1000 milligrams FCM will be administered during outpatient-clinic visit if the cumulative iron dosage has not yet been met. 3. Setting-3: A third dose of 500 milligrams of FCM will be administered at week 12 if ID recurs or persists during follow-up. Each dose will be infused using peripheral venous access over at least 15 minutes. The total duration of the intervention is 12 weeks, after which an endpoint outpatient follow-up assessment takes place at week 24 post-TAVI.

06

What researchers measure

Primary outcomes

  1. Change in Health-related Quality of Life (HRQOL)

    The primary endpoint is the change in HRQOL from baseline (pre-TAVI) to week-24 using the 23-item Kansas City Cardiomyopathy Questionnaire (KCCQ-23) which has been validated in patients undergoing TAVI.

    Time frame: The KCCQ-23 will be filled out pre-TAVI during an outpatient or inpatient geriatric visit, or at home and will be filled out again at week-24 post-TAVI during outpatient visit or at home.

  2. Change in 6-Minute Walk Test (6-MWT)

    The co-primary endpoint is change in exercise capacity from baseline (pre-TAVI) to week-24 using the 6-MWT, which is an established objective means of evaluation exercise capacity in the TAVI population.

    Time frame: 6-MWT is performed pre-TAVI during an outpatient or inpatient geriatric visit and will be measured again at week-24 post-TAVI during outpatient visit.

Secondary outcomes

  1. Cognitive function (MMSE)

    Cognitive function using the Mini Mental State Examination (MMSE)

    Time frame: Measured at week-24 post-TAVI

  2. New York Heart Association (NYHA) functional class

    Time frame: Measured at week-24 post-TAVI

  3. European Quality of Life-5 Dimensions 5 Level Utility Index (EQ-5D-5L-UI) and Visual Analog Scale (EQ-5D-VAS)

    EQ5D comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels (no, slight, moderate, severe, and extreme problems) by which a unique health state per item is determined. These health states are converted into weighted health states (Utility Index or EQ-5D-5L-UI) by applying scores on which full health has a value of 1 and death a value of 0. The Visual Analog Scale (EQ-5D-VAS) is a self-reported score ranging from 0-100 with higher scores indicating better health.

    Time frame: Measured at week-24 post-TAVI

  4. Composite of cardiovascular mortality and heart failure hospitalizations

    Time frame: Measured at week-24 post-TAVI

  5. All-cause mortality

    Time frame: Measured at week-24 post-TAVI

  6. Favourable quality of life (QoL)

    Favourable QoL is defined as survival with a KCCQ-score ≥60 without KCCQ-decline \>10 points from baseline to follow-up (week-24 post-TAVI)

    Time frame: Measured at baseline (pre-TAVI) and week-24 post-TAVI

  7. Patient Global Assessment

    Time frame: Measured at week-24 post-TAVI

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Jul 2028, 47 months after the start.

Of 25 phase 4 interventional studies under Aortic Valve Stenosis, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 70. This study's planned 47 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2026
First posted
Jan 27, 2026
StartActual
Aug 12, 2024
Primary completionEst.
Jul 2028
CompletionEst.
Jul 2028
Last update
Jan 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07370688
Responsible party
Rutger-Jan Nuis (MD, PhD, Erasmus Medical Center) — Principal investigator
First posted
Jan 27, 2026
Start date
Aug 12, 2024
Primary completion
Jul 2028 (estimated)
Completion
Jul 2028 (estimated)
Last update
Jan 27, 2026

Study contacts

Rutger-Jan Nuis, MD, PhD
Contact
r.nuis@erasmusmc.nl
+31614858291

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ferric carboxymaltose

Start the discussion